| Clinically isolated syndrome
Briumvi vs Ponvory
Side-by-side clinical, coverage, and cost comparison for clinically isolated syndrome.Deep comparison between: Briumvi vs Ponvory with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPonvory has a higher rate of injection site reactions vs Briumvi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ponvory but not Briumvi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Briumvi
Ponvory
At A Glance
IV infusion
Every 24 weeks
Anti-CD20 monoclonal antibody
Oral
Once daily
S1P receptor 1 modulator
Indications
- Multiple Sclerosis, Relapsing-Remitting
- Clinically isolated syndrome
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- active secondary progressive multiple sclerosis
Dosing
Multiple Sclerosis, Relapsing-Remitting; Clinically isolated syndrome; Multiple Sclerosis, Secondary Progressive 150 mg IV infusion (first infusion), followed by 450 mg IV infusion 2 weeks later, then 450 mg IV every 24 weeks; pre-medicate with methylprednisolone (or equivalent corticosteroid) and antihistamine before each infusion.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, active secondary progressive multiple sclerosis Initiate with 14-day oral dose titration starting at 2 mg once daily per schedule; maintenance dose is 20 mg orally once daily beginning Day 15.
Contraindications
- Active HBV infection
- History of life-threatening infusion reaction to ublituximab-xiiy
- Myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III or IV heart failure within the last 6 months
- Mobitz type II second-degree or third-degree AV block, sick sinus syndrome, or sino-atrial block without a functioning pacemaker
Adverse Reactions
Most common (>=10%) Infusion reactions, upper respiratory tract infections
Serious Infusion reactions, infections, reduction in immunoglobulins, liver injury
Postmarketing Liver injury, progressive multifocal leukoencephalopathy
Most common (>=10%) Upper respiratory tract infection, hepatic transaminase elevation, hypertension
Serious Infections, bradyarrhythmia and AV conduction delays, respiratory effects, liver injury, increased blood pressure, cutaneous malignancies, macular edema, posterior reversible encephalopathy syndrome, severe increase in disability after stopping
Pharmacology
Anti-CD20 chimeric monoclonal IgG1 antibody with reduced fucose content; binds CD20 on pre-B and mature B lymphocytes and causes cell lysis via antibody-dependent cellular cytolysis and complement-dependent cytolysis.
Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1 and blocks lymphocyte egress from lymph nodes, reducing peripheral blood lymphocyte counts; the therapeutic mechanism in multiple sclerosis may involve reduction of lymphocyte migration into the central nervous system.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Briumvi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Ponvory
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (10/12)
UnitedHealthcare
Briumvi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Ponvory
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Briumvi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Ponvory
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BriumviView full Briumvi profile
PonvoryView full Ponvory profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.